TW202306982A - 具有改善的穩定性的抗tslp fab - Google Patents

具有改善的穩定性的抗tslp fab Download PDF

Info

Publication number
TW202306982A
TW202306982A TW111114769A TW111114769A TW202306982A TW 202306982 A TW202306982 A TW 202306982A TW 111114769 A TW111114769 A TW 111114769A TW 111114769 A TW111114769 A TW 111114769A TW 202306982 A TW202306982 A TW 202306982A
Authority
TW
Taiwan
Prior art keywords
fab
tslp
amino acid
cells
seq
Prior art date
Application number
TW111114769A
Other languages
English (en)
Chinese (zh)
Inventor
羅蘭 威廉 科貝克
艾瑪 蘇珊 柯翰
凱瑟琳 尤金妮娅 亨廷顿
Original Assignee
英商梅迪繆思有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 英商梅迪繆思有限公司 filed Critical 英商梅迪繆思有限公司
Publication of TW202306982A publication Critical patent/TW202306982A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
TW111114769A 2021-04-19 2022-04-19 具有改善的穩定性的抗tslp fab TW202306982A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21169183 2021-04-19
EP21169183.7 2021-04-19

Publications (1)

Publication Number Publication Date
TW202306982A true TW202306982A (zh) 2023-02-16

Family

ID=75588042

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111114769A TW202306982A (zh) 2021-04-19 2022-04-19 具有改善的穩定性的抗tslp fab

Country Status (19)

Country Link
US (1) US20240199730A1 (cg-RX-API-DMAC7.html)
EP (1) EP4326767A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024516962A (cg-RX-API-DMAC7.html)
KR (1) KR20230172508A (cg-RX-API-DMAC7.html)
CN (1) CN117222665A (cg-RX-API-DMAC7.html)
AR (1) AR125379A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022263281A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023021587A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216894A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023003082A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023015286A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230533A (cg-RX-API-DMAC7.html)
EC (1) ECSP23086870A (cg-RX-API-DMAC7.html)
IL (1) IL307651A (cg-RX-API-DMAC7.html)
MX (1) MX2023012266A (cg-RX-API-DMAC7.html)
PH (1) PH12023552762A1 (cg-RX-API-DMAC7.html)
SA (1) SA523451188B1 (cg-RX-API-DMAC7.html)
TW (1) TW202306982A (cg-RX-API-DMAC7.html)
WO (1) WO2022223514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)
US12110324B2 (en) 2022-07-22 2024-10-08 Flagship Pioneering Innovations Vi, Llc Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP)
AR135161A1 (es) 2024-01-29 2026-07-08 Astrazeneca Ab Composiciones de fragmentos de unión a la linfopoyetina estromal tímica (tslp) y métodos de uso de las mismas
USD1126392S1 (en) 2024-05-16 2026-05-12 Astrazeneca Ab Inhaler
US20260034317A1 (en) 2024-05-20 2026-02-05 Medimmune Limited Inhaler and capsule for delivering thymic stromal lymphopoietin (tslp)-binding antibodies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1306272C (zh) 2000-11-17 2007-03-21 罗切斯特大学 筛选编码抗原特异性免疫球蛋白分子或其抗原特异性片段的方法
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
EP3609917A1 (en) * 2017-04-12 2020-02-19 Amgen Inc. Treatment of asthma with anti-tslp antibody
JP7331298B2 (ja) * 2019-09-04 2023-08-23 ビオシオン インコーポレイテッド 抗体結合tslp及びその使用
UA129038C2 (uk) * 2019-10-28 2024-12-25 Медіммуне Лімітед Сухий порошкоподібний склад антитіла, що зв'язує тимічний стромальний лімфопоетин (tslp)

Also Published As

Publication number Publication date
MX2023012266A (es) 2023-10-24
EP4326767A1 (en) 2024-02-28
IL307651A (en) 2023-12-01
KR20230172508A (ko) 2023-12-22
CL2023003082A1 (es) 2024-04-19
BR112023021587A2 (pt) 2023-12-19
AR125379A1 (es) 2023-07-12
US20240199730A1 (en) 2024-06-20
CO2023015286A2 (es) 2024-02-05
CN117222665A (zh) 2023-12-12
SA523451188B1 (ar) 2025-06-22
WO2022223514A1 (en) 2022-10-27
AU2022263281A1 (en) 2023-11-09
PH12023552762A1 (en) 2024-04-15
CA3216894A1 (en) 2022-10-27
AU2022263281A9 (en) 2023-11-16
CR20230533A (es) 2024-04-05
ECSP23086870A (es) 2023-12-29
JP2024516962A (ja) 2024-04-18

Similar Documents

Publication Publication Date Title
US20240199730A1 (en) An anti-tslp fab with improved stability
CN108752476B (zh) 一种pdl-1抗体、其药物组合物及其用途
CN105026428B (zh) PD‑l抗体、其抗原结合片段及其医药用途
CN101970489B (zh) 与hGM-CSF结合的单克隆抗体及包含它的药物组合物
CN111432831B (zh) Il-2突变蛋白及其用途
EP2427212B1 (en) Anti-cd100 antibodies and methods for using the same
CN103974975B (zh) 抗假单胞菌Psl结合分子及其用途
KR101852915B1 (ko) 과립구-대식세포 콜로니 자극 인자에 대한 항체
JP2023075271A (ja) ヒト抗セマフォリン4d抗体
CN112654640B (zh) 抗IL-1β的抗体、其药物组合物及其用途
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
CN114907479B (zh) 抗cd112r抗体及其用途
KR20210145187A (ko) Il-5에 대한 항체를 함유하는 약학적 조성물 및 이의 용도
EP3980065A1 (en) Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
CN115894693A (zh) Trbc1抗体及其应用
CN116574189A (zh) 针对人il-36r和/或人il-1r3的多种抗体及其用途
EA052142B1 (ru) Fab К TSLP С ПОВЫШЕННОЙ СТАБИЛЬНОСТЬЮ
JP6014706B2 (ja) hGM−CSFに結合するモノクローナル抗体および前記抗体を含む医薬組成物
CN115521379B (zh) Pd-1抗体及其用途
CN113166264B (zh) 一种分离的抗原结合蛋白及其用途
CN113164601B (zh) 一种分离的抗原结合蛋白及其用途
CN110300763A (zh) 用于治疗白癜风的抗人cxcr3抗体
WO2025108343A1 (zh) 靶向il-11的抗原结合蛋白
CN115340604A (zh) Tim-3全人源单克隆抗体及其应用
HK1146729B (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same